The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with ...

Imagion shares are on a tear after the US FDA said it had no objections to the proposed conduct of a phase II breast cancer ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer ...

OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein.

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

In one of the first large-scale analyses of antibody-drug conjugates (ADCs) by race, a study presented at the recent American Society of Clinical Oncology (ASCO) meeting found that Black patients with ...